Oregon Prescription Drug Affordability Board

350 Winter Street NE, Salem, OR 97309 | 971-374-3724 | pdab@dcbs.oregon.gov | dfr.oregon.gov/pdab

Agenda

This is a draft agenda and subject to change

Wednesday, **January 21, 2026 – 8:00 a.m.**

Register for meeting: **Zoom link**

Purpose	Subject	Presenter
Informational and vote	Call to order and roll call	Chair Shelley Bailey
Informational	Board declarations of conflict of interest and meetings with entities or individuals related to board activities	Chair Shelley Bailey
Review	**Board review of 12/17/2025 minutes**	Chair Shelley Bailey
Informational	PDAB program update	Sarah Young
Informational	General public comment: limited to 3 minutes per speaker	Chair Shelley Bailey
Discussion and vote	**2025 drug review**: Votes to identify up to nine prescription drugs and at least one insulin product that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in Oregon, pursuant to ORS 646A.694	Cortnee Whitlock
Discussion	Recommendations to include in the 2025 drug review report	Cortnee Whitlock
Informational	Executive session for legal advice pursuant to ORS 192.660(2)(f)	Oregon Department of Justice
Discussion and review	**2026 drug review**: Discussion and review of the prescription drugs and insulin products preliminary lists	Cortnee Whitlock
Break	The board will take a break around 10:30	Chair Shelley Bailey
Informational	Announcements	Chair Shelley Bailey
Vote	Adjournment	Chair Shelley Bailey

Accessibility: Anyone needing assistance due to a disability or language barrier can contact Melissa Stiles at least 48 hours ahead of the meeting at pdab@dcbs.oregon.gov or 971-374-3724. American sign language will be available during the Jan. 21 board meeting.

Oregon Prescription Drug Affordability Board

Oregon Prescription Drug Affordability Board Regular Meeting
Wednesday, December 17, 2025
Draft Minutes

Web link to the meeting video: https://youtu.be/zTyUMuPgpOs
Web link to the meeting materials: https://dfr.oregon.gov/pdab/Documents/20251217-PDAB-document-package.pdf

Call to order: Chair Shelley Bailey called the meeting to order at 8:03 a.m.
Roll call:
Present: Chair Shelley Bailey, Vice Chair Dan Hartung, Lauri Hoagland, Dan Kennedy, Michele Koder, and John Murray
Arrived late: Chris Laman (8:21 a.m.)
Absent: None

Board declarations of conflict of interest and meetings with entities or individuals related to board activities: John Murray provided a statement. View at video minute 00:01:02.

Approval of board minutes: Chair Bailey approved by consensus the Nov. 19, 2025 minutes as shown on Pages 3-4 of the agenda materials. View at video minute 00:02:08.

PDAB program update: Sarah Young, PDAB executive director, provided a program update. View the video at minute 00:02:28.

General public comment: Public comment was received from the following individuals who signed up in advance: Dharia McGrew, PhRMA; Jessica McBride, Oregon Coalition for Affordable Prescriptions; Ranier Simons, Community Access National Network; and Lorren Sandt, Caring Ambassadors. The board received 7 written comments, which are posted on the PDAB website. View at video minute 00:09:23.

Board discussion and vote on annual report: Board members discussed the 2025 annual report and proposed amendments. The board voted unanimously to approve the amended 2025 annual report and submit it to the Oregon Legislature. The approved annual report is posted on the PDAB website. View the discussion and vote at video minute 00:19:26.

MOTION to approve the 2025 annual report as amended by the board today and deliver to the Oregon Legislature by Dec. 31, 2025, as required by ORS 646A.696.
Board Vote:
Motion: Chris Laman
Second: John Murray
Yes: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
No: None
Absent: None
MOTION PASSED 7-0

2026 drug review – presentation of the prescription drugs and insulin products preliminary lists: The board received the draft preliminary lists of prescription drugs and insulin products for the 2026 drug reviews, based on commercial insurer reporting from calendar year 2024. The board began reviewing the list at the Dec. 17 meeting and will continue reviewing and narrowing the lists for further evaluation in 2026. The **preliminary list** of drugs is posted on the PDAB website. View at video minute **00:44:57**.

2025 drug review – continued review of the prescription drugs and insulin products: The board continued its review of the prescription drug and insulin products. The board reviewed 23 prescription drugs and insulin products during its meetings in July, August, September, and October, with additional discussions in November and December. The board will vote in January on a list of up to nine prescription drugs and at least one insulin product for inclusion in a report to the Oregon Legislature in March. Drug reviews are conducted according to ORS 646A.694 and OAR 925-200-0020. Read the detailed **reports for each drug** posted on the PDAB website. View at video minute **01:39:25**.

Announcements: Chair Bailey announced the next board meeting will be Jan. 21, 2026 at 8 a.m. View at video minute **03:31:43**.

Adjournment: Chair Bailey adjourned the meeting at 12 p.m. with all board members in agreement. View at video minute **03:31:57**.

Oregon Prescription Drug Affordability Board

Web links to final reports for the 2025 drug review

Agenda item: 2025 drug review: Votes to identify up to nine prescription drugs and at least one insulin product that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in Oregon, pursuant to ORS 646A.694.

In Table 1 below, click on the prescription drug name to read the final version of the drug review document. This table of information is also available on the **Prescription Drug Affordability Board drug review page**.

Table 1: 2025 Oregon PDAB drug review documents, videos, and minutes web links

Drug review documents	Review date	Meeting video	Meeting minutes
• Vraylar • Entresto • Ajovy • Emgality • Nurtec • Ubrelvy	July 16, 2025	July 16, 2025	July 16, 2025
• Trelegy • Eliquis • Xarelto • Cosentyx • Creon	Aug. 20, 2025	Aug. 20, 2025	Aug. 20, 2025
• Jardiance • Mounjaro • Ozempic • Rybelsus • Trulicity	Sept. 17, 2025	Sept. 17, 2025	Sept. 17, 2025
• Insulin products: **Basaglar KwikPen, Insulin Glargine-yfgn, Lantus, Lantus SoloStar, Semglee, Toujeo Max SoloStar Toujeo SoloStar**	Oct. 15, 2025	Oct. 15, 2025	Oct. 15, 2025

PDAB scoring rubric for 2025 prescription drug cost reviews. Scoring rubric is a decision support tool and not the determinative of drug review outcomes.

	Review Drug	Vraylar	Entresto	Ajovy	Emgality	Nurtec	Ubrelvy
Rubris Critera							
Utilization		Severe	Severe	High	High	High	High
Price evaluation		Moderate	Severe	High	High	High	Severe
Price concessions		Moderate	Low	High	Low	Moderate	Moderate
System and payer costs		High	High	Low	Low	High	Moderate
Enrollee burden		Severe	Moderate	Moderate	High	Moderate	Moderate
Equity impact		Yes	Yes	Yes	Yes	Yes	Yes
Access restrictions		Yes	No	Yes	Yes	Yes	Yes
Less expensive therapeutic alternatives available		Yes	Yes	Yes	Yes	Yes	Yes
Steakholder input identify		Yes	No	Yes	Yes	Yes	Yes
Patent expirations more than 18 months		No	**No**	Yes	Yes	No	Yes
Excluded from MFP		No	No	Yes	Yes	Yes	Yes
Scoring totals		14	11	13	12	13	14

***Bolded words indicate a change in scoring**

*score update 12/23/25

	Review Drug	Trelegy	Eliquis	Xarelto	Cosentyx	Creon
Rubris Critera						
Utilization		Severe	Severe	Severe	High	High
Price evaluation		Moderate	Severe	High	Severe	Severe
Price concessions		High	Low	High	High	Severe
System and payer costs		High	Severe	Severe	Severe	High
Enrollee burden		Moderate	Moderate	Moderate	Severe	Moderate
Equity impact		Yes	Yes	Yes	Yes	Yes
Access restrictions		No	No	No	Yes	no
Less expensive therapeutic alternatives available		Yes	Yes	Yes	Yes	Yes
Steakholder input identify		No	Yes	Yes	Yes	Yes
Patent expirations more than 18 months		Yes	Yes	Yes	Yes	Yes
Excluded from MFP		No	No	No	Yes	Yes
Scoring totals		12	14	15	19	16

***Bolded words indicate a change in scoring**

	Review Drug	Jardiance	Mounjaro	Ozempic	Rybelsus	Trulicity
Rubris Critera						
Utilization		Severe	High	Severe	High	Severe
Price evaluation		High	High	High	Moderate	Severe
Price concessions		Moderate	High	high	Moderate	High
System and payer costs		Severe	High	Severe	High	Severe
Enrollee burden		High	Moderate	Moderate	Moderate	Moderate
Equity impact		Yes	Yes	Yes	Yes	Yes
Access restrictions		no	Yes	Yes	Yes	Yes
Less expensive therapeutic alternatives available		Yes	Yes	Yes	Yes	Yes
Steakholder input identify		Yes	Yes	Yes	No	Yes
Patent expirations more than 18 months		No	Yes	Yes	Yes	Yes
Excluded from MFP		No	**Yes**	No	No	Yes
Scoring totals		14	15	16	11	18

***Bolded words indicate a change in scoring**

*score update 12/23/25

Oregon Prescription Drug Affordability Board

Prescription Drug Affordability Board

2026 drug review roadmap

Jan. 21, 2026

Draft 2025-2026 drug review (DR) & annual report calendar

	Jan 21, 2026 PDAB Mtg	Feb 18 PDAB Mtg	Mar 18 PDAB Mtg	Apr 15 PDAB Mtg	May 20 PDAB Mtg	Jun 17 PDAB Mtg
2025 Rx Subset list **2025 Insulin Subset list**	Board Rx **vote**	Review draft report	**Approve final report**			
Additional recommendations	Board discussion	Board decision and vote	**Approve in final report**			
2026 Preliminary Rx and insulin drug list	Board review and discussion	Board review and discussion	Board discussion and subset selected			
Data call of Rx subset list		Rx and insulin		Analysis write-up		Shared with Board
Public outreach				Outreach events across Oregon		

Oregon Prescription Drug Affordability Board

Oregon PDAB authority to review drugs with orphan-drug designations

Cortnee Whitlock, senior policy analyst

January 21, 2026

Purpose of briefing

- Clarify how federal orphan-drug designation (rare disease or condition) interacts with Oregon PDAB authority
- Explain what ORS 646A.694 exempts — and what it does *not exempt*
- Show how OAR 925-200-0020(2)(n) guides board decisions
- Provide an interpretation for reviewing drugs with multiple indications

Federal Law: What 21 U.S.C. § 360bb does

- Defines how a **drug** receives a designation for a rare disease or condition (often called orphan-drug designation)
- Does **not** regulate pricing, affordability, or state review
- Does **not** preempt state PDAB authority

FDA's orphan-designation program is built on 21 U.S.C. § 360bb and 21 C.F.R. Part 316

- FDA guidance on how the agency grants orphan designation to drugs intended to treat rare diseases or conditions.
- That authority comes from the Orphan Drug Act, which includes **21 U.S.C. § 360bb**.



Oregon Prescription Drug Affordability Board

4

ORS 646A.694: Oregon's statutory drug review framework

ORS 646A.694 (2) states:

"A drug that is designated… under 21 U.S.C. 360bb, as a drug for a rare disease or condition is **not subject to review under subsection (1) of this section**."

What this means:

- The **orphan indication** is exempt for review
- ORS 646A.694 (2) does **not** exempt the entire drug
- ORS 646A.694 (2) does **not** prohibit review of **non-orphan indications**

5

What ORS 646A.694 (2) *does not say*

- That all uses of drug with orphan-designation are exempt from review
- That PDAB cannot review the drug for other indications
- **Important**: The exemption is **orphan indication-specific**, not **drug-wide**.

Administrative Rule: OAR 925-200-0020(2)(n)

A drug used for other indications, in addition to a rare disease or condition, is not exempt from an affordability review for those other indications.

This rule:

- Interprets ORS 646A.694 (2) consistently with legislative intent
- Confirms PDAB ability to review non-orphan uses
- Prevents shielding high-cost drugs with a single orphan indication

7

Legal hierarchy

1. **Federal law 21 U.S.C. § 360bb** → Defines orphan designation; does **not** restrict state affordability review
2. **State statute ORS 646A.694 (2)** → Exempts only the orphan indication
3. **Administrative rule OAR 925-200-0020** → Clarifies that non-orphan indications remain reviewable

Result: PDAB may review any drug for its **non-orphan indications**, even if it has an orphan designation.

Practical application for PDAB

When a drug has:

- **Only an orphan indication:** → Exempt from review
- **Orphan + non-orphan indications:** → PDAB may review the drug for **non-orphan uses**
- **Off-label use:** → PDAB may consider off-label utilization when assessing affordability

9

Why this matters

- Many drugs with orphan designations have large commercial markets
- Oregon's statute and rule prevents inappropriate exemptions
- Ensures PDAB can address affordability challenges affecting Oregon patients and its healthcare system
- Aligns with PDAB mission and best practices

Summary

- **21 U.S.C. § 360bb** defines how a **drug** receives orphan designation, and **does not** restrict PDAB authority to review drugs that treat other conditions besides their rare disease or condition designation
- **ORS 646A.694 (2)** exempts only the **orphan-drug designation**
- **OAR 925-200-0020(2)(n)** confirms PDAB may review non-orphan indications

Oregon Prescription Drug Affordability Board

Web links to preliminary drug lists for 2026 drug review

Agenda item: 2026 drug review: Discussion and review of the prescription drugs and insulin products preliminary lists.

Below, click on the file name below to view the prescription drugs and insulin products preliminary lists in Excel spreadsheets. The lists are for the 2026 drug review using data information from 2024. This information is also available on the **Prescription Drug Affordability Board drug review page**.

- **Prescription drugs preliminary list:** **https://dfr.oregon.gov/pdab/Documents/2026_Drug_Review_Preliminary_List_v02.xlsx**
- **Insulin products preliminary list:** **https://dfr.oregon.gov/pdab/Documents/2026_Drug_Review_Insulin_Preliminary_List_v02.xlsx**

DO YOU THINK YOUR PRESCRIPTION DRUGS COST TOO MUCH?

Learn why drug costs are so high

Oregon Prescription Drug Affordability Board helps to protect Oregonians and the health care system from the high cost of prescription drugs. The board wants to reduce financial burdens for patients.

Help us identify solutions to high drug costs

Please come share your story at a community forum with board staff about how prescription drug prices and medication costs have affected you.



In-person forums

Salem – Tuesday, May 5, 5 to 6:30 p.m.
Salem Public Library
585 Liberty St. SE
Salem

Redmond – Thursday, May 7, 5 to 6:30 p.m.
Redmond Public Library
827 SW Deschutes Ave.
Redmond

Portland – Tuesday, May 12, 6 to 7:30 p.m.
Asian Health Center
9035 SE Foster Road
Portland

Beaverton – Monday, May 18, 5 to 6:30 p.m.
Beaverton Public Library
12375 SW Fifth St.
Beaverton

Oregon Prescription Drug
Affordability Board

Online forums

Join any ZoomGov meeting at the scheduled time at zoomgov.com/join.

Enter the meeting ID and passcode

Passcode: OregonPDAB
Dial in by phone: 669-254-5252

Tuesday, April 28, 7 to 8:30 p.m.
Join ZoomGov Meeting
Meeting ID: 161 635 9753

Monday, May 11, noon to 1:30 p.m.
Join ZoomGov Meeting
Meeting ID: 160 556 2737

Wednesday, May 13, 6:30 to 8:30 p.m.
Join ZoomGov Meeting
Meeting ID: 161 233 0328
En Español

PDAB board meeting:

Wednesday, May 20, 8 a.m. to noon
Join ZoomGov Meeting
Meeting ID: 161 233 0328

Share your story in the online feedback form:
dfr.oregon.gov/pdab/